Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07279766 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

Study acronym: DAN-COVID
StatusCompleted
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Final enrollment: 41060 participants (planned 285000)
    • Primary completion date changed from estimate of Aug 2026 to Aug 26, 2026
    • Study completion date changed from estimate of Aug 2026 to Sep 5, 2026
    • Eligibility criteria expanded, about 25 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.
Trial Details
NCT Number NCT07279766
Lead Sponsor Tor Biering-Sørensen
Collaborators: ModernaTX, Inc.
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19, Respiratory Tract Diseases
Enrollment 41,060 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov